The Respiratory Syncytial Virus Foundation (ReSViNET) is a global, independent non-profit organization focused on reducing the health and economic burden of respiratory syncytial virus (RSV). It brings together clinicians, researchers, public health experts, patient representatives, and industry stakeholders to advance prevention, diagnosis, and treatment of RSV across age groups.
ReSViNET facilitates collaborative research, data sharing, and translational initiatives; disseminates scientific evidence; and supports education for healthcare professionals and the public. The foundation also convenes expert networks and working groups to inform best practices and policy, aiming to accelerate the development and responsible use of vaccines, antibodies, and therapeutics for RSV.
Also known as ReSViNET.
ENFLONSIA shows consistent safety and efficacy in high-risk infants over two RSV seasons, supporting expanded use for children under 2.
